PRECOMPETITIVE COLLABORATIONS IN PHARMACEUTICAL INDUSTRY - Collaborative Computational Technologies for Biomedical Research - page 83

Qu é bec
Consortium for
Drug Discovery
(CQDM),
www.cqdm.org

CQDM is a nonprofi t organization whose mission is to
identify, fund, and support research projects carried
out in partnership between the academic and
hospital milieus in the public sector and the
biotechnology and contract research organizations
in the private sector. Research projects funded by
CQDM aim at developing tools or enabling
technologies that facilitate and accelerate the drug
discovery process. AZ, Merck, and Pfi zer are the
pharma partners.

Stem Cells for
Safer
Medicines,
www.sc4sm.org

Its aim is to enable the creation of a bank of stem
cells, open protocols, and standardized systems in
stem cell technology to enable consistent
differentiation of stem cells into stable homogenous
populations of particular cell types, with
physiologically relevant phenotypes suitable for
toxicology testing in high-throughput platforms.

REFERENCES

1. Weber S . The Success of Open Source . Cambridge, MA: Harvard University Press,
2004 .
2. Woodcock J . Precompetitive research: A new prescription for drug development?
Clin Pharmacol ther 2010 ; 87 ( 5 ): 521 - 523 .
3. Rawlins M . Cutting the cost of drug development? Nature Drug Discov 2004 .
3 : 361 - 364 .
4. DiMasi J , Hansen RW , Grabowski HG . The price of innovation: New estimates of
drug development costs. J. Health Econ 2003 ; 22 : 151 - 185 .
5. Wagner JA . Open minded to open innovation and precompetitive collaboration .
Clin Pharmacol Thera 2010 ; 87 ( 5 ): 511 - 515 .
6. Wagner JA , et al. The Biomarkers Consortium: Practice and pitfalls of open - source
precompetitive collaboration. Clin Pharmacol Ther 2010 ; 87 ( 5 ): 539 - 542 .
7. Woosley R , Myers RT , Goodsaid F . The Critical Path Institute ' s approach to sharing
and advancing regulatory science. Clin Pharmacol Ther 2010 ; 87 ( 5 ): 530 - 533 .
8. Gamo F - J , et al. Thousands of chemical starting points for antimicrobial lead iden-
tifi cation. Nature 2010 ; 465 : 305 - 310 .
9. Guiguemde WA , et al. Chemical genetics of Plasmodium falciparium . Nature
2010 ; 465 : 311 - 315 .
10. Strauss S . Pharma embraces open source models . Nature Biotechnol 2010 ; 28 :
631 - 634 .
11. Joint technology initiatives: Background, state - of - play and main features . Commis-
sion Staff Working Document SEC(2007) 692, Brussels; CEC, 2007.
12. IMI fact sheet. Available: ftp://ftp.cordis.europa.eu/pub/fp7/docs/factsheet2_imi_
en.pdf .